FEDERAL
State
The LOANS for Biomedical Research Act: Boosting Medical Innovation
H.R. 7539, also known as the "Long-term Opportunities for Advancing New Studies for Biomedical Research Act" is a bill introduced in Congress to create a new way of funding important medical research.
Key Points:
Creates "BioBonds": The bill establishes a program where special bonds, called BioBonds, are sold to investors. The money from these bonds goes to fund clinical trials for new drugs and medical devices.
Focuses on Unmet Medical Needs: The research funded by BioBonds must address medical needs that currently lack effective treatments.
Government Backing: The U.S. Treasury would guarantee up to 90% of each BioBond, making them a safer investment and encouraging more funding for medical research.
Diverse Research: The program aims to support a wide range of biomedical projects, not favoring any single disease or disability.
Protects Taxpayers: The bill includes measures to protect taxpayer interests, such as reinvesting proceeds and giving the government priority in repayment.
Loan Limits: There's a $25 million per year limit on loans to any single recipient to ensure fair distribution of funds.
Why is it Important?
Addresses Funding Gaps
Accelerates Innovation
Tackles Unmet Needs
A creative approach to boosting medical research funding and accelerating development of new treatments.
Support H.R. 7539 Today!
Improving Seniors’ Timely Access to Care Act
CMS Prior Authorization
CMS Prior Authorization
A new CMS rule - CMS-1717-FC - requires a new prior authorization process for neurotoxin injections for patients in the hospital outpatient setting. Since the rule's implementation on July 1, many migraine disease patients have experienced new challenges accessing their treatments, including delays or denials. Meanwhile, health care providers are seeing new paperwork burdens and barriers in getting the right care for their patients.
Policymakers need to hear from you! Tell CMS and your Member of Congress this policy needs to be updated. Weigh in through our survey, write your legislator and share your experience online.
Take Survey
This survey explores how a new rule from the Centers for Medicare and Medicaid Services impacts access to care for people living with migraine disease and other conditions. The rule requires prior authorization before any neurotoxin injection is provided in an outpatient hospital setting.
Survey responses will be used to provide input to members of Congress so they are made aware of the rule’s adverse effects.
Contact Your Legislator
Congress must act to ask CMS to suspend this rule immediately until such a time as it can be implemented appropriately and without causing delays in care. Without immediate action, patients and providers will continue to face barriers in accessing their appropriate, effective treatments.
Feel free to edit the letter and share your personal experience with lawmakers.
Join the Conversation
Tweet these messages to join the conversation on social media.
A new CMS rule instituting prior authorization for neurotoxin injections is delaying care for people living with #migraine disease. @CMSgov should suspend this policy until it can be implemented without delays for patients. Learn more & take action: https://bit.ly/3dlDdtS
A new CMS rule implementing prior authorization for neurotoxins has negatively impacted patients by delaying or denying them access to the treatments their provider has prescribed. @cmsgov should protect access by suspending this rule. Learn more: https://bit.ly/3dlDdtS
.@CMSgov's decision to institute new prior authorizations for botulinum toxin injections has led to unintended health outcomes for people living with #migraine disease. Ask your representative to urge CMS to suspend this policy here: https://bit.ly/3dvztpF
.@CMSgov’s new prior authorization rule is creating barriers to access for people living with #migraine disease. Let your voice be heard in this brief survey: https://bit.ly/36XSv71
HMPF Capitol Hill Policy Forum
Featured
Migraine Matters
Migraine At Work
Migraine at Work, a project of The Headache & Migraine Policy Forum, has launched a new website to support employers and employees with the tools they need to build happier, healthier and more productive workplaces. Whether you’re looking to initiate a positive conversation with your employer or simply learn about effective strategies for managing your disease at work, this website is a great place to start.
Amgen is a founding sponsor of Migraine at Work.
File A Complaint
CONSUMER GUIDE
Have you been denied access to the treatment you need to manage your migraine disease? HMPF's "Guide to Filing an Insurance Complaint for Migraine Patients and Providers" outlines how you can file an insurance complaint in your state.
FILE A COMPLAINT
Click on your state below to submit a complaint.
WPSI - Well-Woman Visit
For many women, her annual well-woman appointment may be the one time a year she speaks with a doctor about her health. And given that women suffer from migraines at a rate three times that of men, amending the Well-Women screening to include questions about the disease has the potential to benefit many women.
Featured
